| Symbol | CGEM |
|---|---|
| Name | CULLINAN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | ONE MAIN STREET,SUITE 520, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 410-4650 |
| Fax | — |
| — | |
| Website | https://cullinantherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator. Additional info from NASDAQ: |
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Read moreNew Form S-3ASR - Cullinan Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-183596 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Cullinan Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-183472 <b>Size:</b> 313 KB
Read moreNew Form DEF 14A - Cullinan Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-183465 <b>Size:</b> 5 MB
Read moreNew Form ARS - Cullinan Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-183459 <b>Size:</b> 2 MB
Read moreNew Form SCHEDULE 13G/A - Cullinan Therapeutics, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-001005 <b>Size:</b> 7 KB
Read more(30% Negative) CULLINAN THERAPEUTICS, INC. (CGEM) Reports Q1 2026 Financial Results
Read moreNew Form S-8 - Cullinan Therapeutics, Inc. <b>Filed:</b> 2026-03-10 <b>AccNo:</b> 0001193125-26-099373 <b>Size:</b> 327 KB
Read moreMichaelson Jennifer 🟡 adjusted position in 8.0K shares (1 derivative) of Cullinan Therapeutics, Inc. (CGEM) at $15.68 Transaction Date: Mar 05, 2026 | Filing ID: 098781
Read more📋 JENNIFER MICHAELSON (Officer) plans to sell 8K shares of CULLINAN THERAPEUTICS, INC. (at $16.30 each, total $130K) Filed: Mar 05, 2026 | ID: 002270
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07041099 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager,… | Phase1 | Sjögren | Recruiting | 2025-10-01 | 2029-03-15 | ClinicalTrials.gov |
| NCT06994143 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager,… | Phase1 | Rheumatoid Arthritis (RA | Recruiting | 2025-05-19 | 2028-12-30 | ClinicalTrials.gov |
| NCT06613360 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager,… | Phase1 | SLE | Recruiting | 2025-01-21 | 2027-12-01 | ClinicalTrials.gov |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refr… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2024-09-03 | 2027-03-01 | ClinicalTrials.gov |
| NCT06035744 | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced S… | Phase1 | Advanced Solid Tumor | Recruiting | 2023-12-12 | 2028-06-01 | ClinicalTrials.gov |
| NCT05879744 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hod… | Phase1 | NHL | Active_Not_Recruiting | 2023-05-31 | 2027-04-01 | ClinicalTrials.gov |
| NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or My… | Phase1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Recruiting | 2021-11-18 | 2027-06-01 | ClinicalTrials.gov |
| NCT05117476 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Soli… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2021-10-29 | 2026-06-01 | ClinicalTrials.gov |
| NCT04036682 | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | Phase1 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2019-10-31 | 2026-03-31 | ClinicalTrials.gov |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive … | Phase1 | Nasopharyngeal Carcinoma | Terminated | 2019-04-04 | 2020-08-08 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| VK-2019 | Other | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03682055 |
| CLN-978 | Other | Phase PHASE1 | NHL | ACTIVE_NOT_RECRUITING | NCT05879744 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06035744 |
| CLN-617 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06035744 |
| CLN-081 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04036682 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-619 | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06381141 |
| CLN-978 | Other | Phase PHASE1 | Sjögren | RECRUITING | NCT07041099 |
| Datopotamab deruxtecan-dlnk (Dato-DXd) | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| pemetrexed | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Carboplatin AUC 6 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| CLN-619 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| CLN-049 | Other | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | RECRUITING | NCT05143996 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-617 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06035744 |
| CLN-978 | DRUG | Phase PHASE1 | Sjögren | RECRUITING | NCT07041099 |
| CLN-049 | DRUG | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | RECRUITING | NCT05143996 |
| Datopotamab deruxtecan-dlnk (Dato-DXd) | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| pemetrexed | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Carboplatin AUC 6 | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Paclitaxel | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Pembrolizumab | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06035744 |
| CLN-619 | DRUG | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06381141 |
| CLN-081 | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04036682 |
| VK-2019 | DRUG | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03682055 |